Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 53,572 | 56,953 | 90,466 | 144,761 | 143,893 |
| Receivables | 19,572 | 17,781 | 40,284 | 23,094 | 81,869 |
| Inventories | 20,905 | 20,604 | 21,568 | 40,039 | 36,272 |
| TOTAL | $118,447 | $120,719 | $185,182 | $237,512 | $304,163 |
| Non-Current Assets | |||||
| PPE Net | 4,419 | 4,816 | 5,214 | 5,622 | 6,035 |
| Intangibles | 113,107 | 118,127 | 131,128 | 136,148 | 145,159 |
| Other Non-Current Assets | 17,739 | 33,196 | 34,530 | 56,612 | 66,447 |
| TOTAL | $135,265 | $156,139 | $170,872 | $198,382 | $217,641 |
| Total Assets | $253,712 | $276,858 | $356,054 | $435,894 | $521,804 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 24,000 | 24,000 | 32,000 | 65,947 | 98,158 |
| Accounts payable and accrued liabilities | 11,776 | 12,577 | 18,021 | 19,708 | 24,944 |
| Accrued Expenses | 56,408 | 46,367 | 75,777 | 87,364 | 91,284 |
| Other current liabilities | N/A | N/A | N/A | 13,681 | 14,247 |
| TOTAL | $92,184 | $82,944 | $129,536 | $187,965 | $233,680 |
| Non-Current Liabilities | |||||
| Long Term Debt | 18,486 | 26,296 | 34,078 | N/A | N/A |
| Deferred Revenues | 0 | 0 | 3,738 | 1,265 | 5,047 |
| Other Non-Current Liabilities | 126,553 | 138,674 | 143,914 | 190,780 | 150,795 |
| TOTAL | $188,335 | $208,266 | $221,288 | $234,076 | $225,824 |
| Total Liabilities | $280,519 | $291,210 | $350,824 | $422,041 | $459,504 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 188,314 | 185,928 | 184,248 | 183,962 | 183,849 |
| Common Shares | 2 | 2 | 2 | 2 | 2 |
| Retained earnings | -1,595,075 | -1,579,130 | -1,557,025 | -1,545,361 | -1,493,496 |
| Other shareholders' equity | 6 | 6 | 6 | 6 | 6 |
| TOTAL | $-26,807 | $-14,352 | $5,230 | $13,853 | $62,300 |
| Total Liabilities And Equity | $253,712 | $276,858 | $356,054 | $435,894 | $521,804 |